-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Oncotelic Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and change rate from Q2 2019 to Q3 2025.
- Oncotelic Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was -$623K, a 586% decline year-over-year.
- Oncotelic Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was -$1.23M, a 4.78% increase year-over-year.
- Oncotelic Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was -$1.2M, a 22.8% increase from 2023.
- Oncotelic Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$1.56M, a 111% decline from 2022.
- Oncotelic Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $14.4M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)